FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4375845058> ?p ?o ?g. }

• W4375845058 abstract "Deep vein thrombosis (DVT) is a common complication in cancer. Although thromboprophylaxis in cancer patients is recommended by the guidelines, clinicians' use of thromboprophylaxis remains limited due to cost, bleeding complications, and reluctance to give injectable anticoagulants. Inflammation plays essential roles in the pathogenesis of cancer-associated thrombosis. Owing to its ability to decrease proinflammatory cytokines, statins have anti-inflammatory properties. Thus, statins can be possibly utilized as thromboprophylaxis therapy in cancer patients undergoing chemotherapy.To compare the effectiveness of atorvastatin and rivaroxaban for DVT prevention in high-risk thrombosis patients with cancer undergoing chemotherapy.Double-blind, randomized controlled trial involving cancer patients with high-risk of thrombosis undergoing chemotherapy. We randomly assigned patients without deep-vein thrombosis at screening to receive atorvastatin 20 mg or rivaroxaban 10 mg daily for up to 90 days. Doppler ultrasonography was performed 90 days following chemotherapy to diagnose DVT. Average cost-effectiveness analysis was performed to analyze the cost of atorvastatin compared to rivaroxaban.Of the eighty six patients who underwent randomization, primary efficacy end point was observed in 1 of 42 patients (2.3%) in the atorvastatin group and in 1 of 44 (2.2%) in the rivaroxaban group (Odds Ratio [OR], 0.953; 95% confidence interval [CI], 0.240 to 3.971; p = 1.000). There was a significant difference in the incidence of major bleeding, 2 of 42 patients (4.8%) in the atorvastatin group and 12 of 44 (27.3%) in the rivaroxaban group (OR, 0.257; 95% CI, 0.07 to 0.94; p = 0.007). The average cost-effectiveness ratio of using atorvastatin was lower than that of rivaroxaban.Atorvastatin did not differ significantly from rivaroxaban in reducing the incidence of DVT, lower bleeding risk, and cost-effectiveness for thromboprophylaxis in high-risk thrombosis patients with cancer undergoing chemotherapy. The presence of limited statistical power and wide confidence intervals in this study needs further study to strengthen the efficacy of atorvastatin as DVT prophylaxis in cancer patients.ISRCTN71891829, Registration Date: 17/12/2020." @default.
• W4375845058 created "2023-05-10" @default.
• W4375845058 creator A5030338535 @default.
• W4375845058 creator A5033731252 @default.
• W4375845058 creator A5046230606 @default.
• W4375845058 creator A5046626209 @default.
• W4375845058 creator A5050821888 @default.
• W4375845058 creator A5060412661 @default.
• W4375845058 creator A5068252309 @default.
• W4375845058 creator A5069473771 @default.
• W4375845058 creator A5084489821 @default.
• W4375845058 creator A5086252860 @default.
• W4375845058 creator A5087573066 @default.
• W4375845058 date "2023-05-08" @default.
• W4375845058 modified "2023-09-26" @default.
• W4375845058 title "The effectiveness of atorvastatin for the prevention of deep vein thrombosis in cancer patients undergoing chemotherapy" @default.
• W4375845058 cites W1065629687 @default.
• W4375845058 cites W1589295587 @default.
• W4375845058 cites W1947293078 @default.
• W4375845058 cites W1967455552 @default.
• W4375845058 cites W1985748013 @default.
• W4375845058 cites W1992661527 @default.
• W4375845058 cites W2001663077 @default.
• W4375845058 cites W2013945874 @default.
• W4375845058 cites W2018856451 @default.
• W4375845058 cites W2020579106 @default.
• W4375845058 cites W2030578531 @default.
• W4375845058 cites W2036385193 @default.
• W4375845058 cites W2041113507 @default.
• W4375845058 cites W2057542355 @default.
• W4375845058 cites W2065836419 @default.
• W4375845058 cites W2075535107 @default.
• W4375845058 cites W2093389482 @default.
• W4375845058 cites W2104370487 @default.
• W4375845058 cites W2104514360 @default.
• W4375845058 cites W2115787552 @default.
• W4375845058 cites W2121529216 @default.
• W4375845058 cites W2124057402 @default.
• W4375845058 cites W2132381095 @default.
• W4375845058 cites W2139562241 @default.
• W4375845058 cites W2157446158 @default.
• W4375845058 cites W2167728254 @default.
• W4375845058 cites W2296631214 @default.
• W4375845058 cites W2415027282 @default.
• W4375845058 cites W2528057329 @default.
• W4375845058 cites W2560156627 @default.
• W4375845058 cites W2762990020 @default.
• W4375845058 cites W2771472591 @default.
• W4375845058 cites W2798140734 @default.
• W4375845058 cites W2799522017 @default.
• W4375845058 cites W2803403137 @default.
• W4375845058 cites W2886381914 @default.
• W4375845058 cites W2900034165 @default.
• W4375845058 cites W2901356730 @default.
• W4375845058 cites W2917722773 @default.
• W4375845058 cites W2935041100 @default.
• W4375845058 cites W2966354200 @default.
• W4375845058 cites W2972019042 @default.
• W4375845058 cites W2979556299 @default.
• W4375845058 cites W2989714602 @default.
• W4375845058 cites W3008657804 @default.
• W4375845058 cites W3093560427 @default.
• W4375845058 cites W3129818723 @default.
• W4375845058 cites W3194200408 @default.
• W4375845058 cites W4232744709 @default.
• W4375845058 doi "https://doi.org/10.1186/s12959-023-00497-0" @default.
• W4375845058 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37150824" @default.
• W4375845058 hasPublicationYear "2023" @default.
• W4375845058 type Work @default.
• W4375845058 citedByCount "0" @default.
• W4375845058 crossrefType "journal-article" @default.
• W4375845058 hasAuthorship W4375845058A5030338535 @default.
• W4375845058 hasAuthorship W4375845058A5033731252 @default.
• W4375845058 hasAuthorship W4375845058A5046230606 @default.
• W4375845058 hasAuthorship W4375845058A5046626209 @default.
• W4375845058 hasAuthorship W4375845058A5050821888 @default.
• W4375845058 hasAuthorship W4375845058A5060412661 @default.
• W4375845058 hasAuthorship W4375845058A5068252309 @default.
• W4375845058 hasAuthorship W4375845058A5069473771 @default.
• W4375845058 hasAuthorship W4375845058A5084489821 @default.
• W4375845058 hasAuthorship W4375845058A5086252860 @default.
• W4375845058 hasAuthorship W4375845058A5087573066 @default.
• W4375845058 hasBestOaLocation W43758450581 @default.
• W4375845058 hasConcept C121608353 @default.
• W4375845058 hasConcept C126322002 @default.
• W4375845058 hasConcept C141071460 @default.
• W4375845058 hasConcept C168563851 @default.
• W4375845058 hasConcept C2776301958 @default.
• W4375845058 hasConcept C2776694085 @default.
• W4375845058 hasConcept C2777482532 @default.
• W4375845058 hasConcept C2778661090 @default.
• W4375845058 hasConcept C2778959117 @default.
• W4375845058 hasConcept C2779161974 @default.
• W4375845058 hasConcept C2780868729 @default.
• W4375845058 hasConcept C71924100 @default.
• W4375845058 hasConceptScore W4375845058C121608353 @default.
• W4375845058 hasConceptScore W4375845058C126322002 @default.
• W4375845058 hasConceptScore W4375845058C141071460 @default.
• W4375845058 hasConceptScore W4375845058C168563851 @default.
• W4375845058 hasConceptScore W4375845058C2776301958 @default.

• next